Tong Ming Liu | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Dr. Tong Ming Liu |  Stem Cell Research | Best Researcher Award

Institute of Molecular and Cell Biology | Singapore

Dr. Tong Ming Liu’s research focuses on advancing gene and cell therapy through innovative studies on human mesenchymal stem cells (hMSCs) and induced pluripotent stem cells (iPSCs). His work explores the mechanisms governing mesenchymal stem cell stemness, potency, and ageing, with the goal of improving the therapeutic efficacy and manufacturing quality of MSC-based treatments. A central aspect of his research is identifying and characterizing critical quality attributes (CQAs) in MSC manufacturing to ensure consistent and safe clinical applications. Dr. Liu also investigates disease modeling of bone and cartilage disorders using iPSC-derived MSCs to facilitate drug screening and gene correction strategies. His recent projects include the development of optimized media for iPSC, iPSC-MSC, and MSC culture, as well as identifying novel biomarkers to select high-quality MSCs for regenerative medicine. Through his studies, he aims to enhance the scalability, functionality, and translational potential of stem cell therapies. His findings have been recognized in scientific forums such as the EVANTICA Symposium and Singapore Cell and Gene Therapy Conference, underscoring his contribution to the development of efficient MSC-derived extracellular vesicle (MSC-EV) optimization and regenerative therapy innovations.

Profiles: Google Scholar | Scopus | Orcid

Featured Publications:

Liu, T. M.*, Tew, W., Yang, Z., Lim, B., Hui, J. H. P., Lee, E. H., Loh, Y.-H., & Cool, S. (2025). Understanding the molecular basis of mesenchymal stem cell stemness: Implications for clinical applications. Cell Death & Disease, 16(1), 778.

Liu, T. M.* (2025). MSC-EVs: Pioneering the next generation of biomedical applications. World Journal of Stem Cells, 17(6), 108197.

Liu, T. M.*, & Wu, Y. (2023). Advancing gene and cell therapy using human mesenchymal stem cells. Frontiers in Cell and Developmental Biology, 11, 1294460.

Shou, Y., Liu, L., Le, Z., Lee, K. L., Li, X., Koh, D. Z., Wang, Y., Liu, T. M., Yang, Z., Lim, C. T., Cheung, C., & Tay, A. (2023). Mechano-responsive hydrogel for directing stem cell manufacturing and therapy. Bioactive Materials, 24, 387–400.

Liu, T. M.* (2021). Application of mesenchymal stem cells derived from human pluripotent stem cells in regenerative medicine. World Journal of Stem Cells, 13(12), 1826–1844.

Srinivasan, A., Sathiyanathan, P., Yin, L., Liu, T. M., Lam, A., Ravikumar, M., Smith, R. A. A., Loh, H. P., Zhang, Y., Ling, L., Ng, S. K., Yang, Y. S., Lezhava, A., Hui, J., Oh, S., & Cool, S. M. (2022). Strategies to enhance immunomodulatory properties and reduce heterogeneity in mesenchymal stromal cells during ex vivo expansion. Cytotherapy, 24(5), 456–472.

Liu, T. M.*, Yildirim, E. D., Li, P., Fang, H. T., Denslin, V., Kumar, V., Loh, Y.-H., Lee, E. H., Cool, S. M., Teh, B. T., Hui, J. H., Lim, B., & Shyh-Chang, N. (2020). Ascorbate and iron are required for the specification and long-term self-renewal of human skeletal mesenchymal stromal cells. Stem Cell Reports, 14(2), 210–225.

Kelly Bosak | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Dr. Kelly Bosak | Stem Cell Research | Best Researcher Award

University of Kansas Medical Center | United States

Dr. Kelly A. Bosak, PhD, APRN, ANP-BC, FHFSA, is a tenured Associate Professor at the University of Kansas Medical Center and a nationally recognized expert in heart failure care, nursing science, and implementation research. With a strong background in advanced practice nursing and nursing administration, Dr. Bosak has made significant contributions to interdisciplinary research focused on improving clinical outcomes in cardiology, rural health, and chronic disease management. Her peer-reviewed work spans high-impact journals such as The Journal of Cardiac Failure, Implementation Science, and The Journal for Nurse Practitioners, reflecting her leadership in both clinical practice and academic scholarship. Dr. Bosak has authored or co-authored over 30 peer-reviewed publications, with a Scopus h-index of 10, over 450 citations, and 32 documents indexed in major databases. She has played a pivotal role in national reports from the Heart Failure Society of America and led multiple implementation science projects aimed at integrating evidence-based interventions into routine care. Her current research emphasizes digital health innovation and workforce development in underserved communities. Dr. Bosak’s interdisciplinary collaborations and translational research continue to shape evidence-based practice and policy in cardiovascular nursing and advanced practice nursing education.

Profiles: Google Scholar | Scopus

Featured Publications:

  • “Return on Investment of a Nurse Practitioner Fellowship Program”

  • “Interprofessional Education for Improving Workforce Capacity to Treat COPD and Long COVID in Rural Communities”

  • “Shared Decision Making for the Pulmonary Artery Monitoring Device for Patients with Heart Failure”

  • “Implementation of a SmartPhrase for Exercise in the Electronic Health Record for Individuals with Heart Failure”

  • “Implementing a Standardized Workflow for Early Detection of Steroid-Induced Hyperglycemia in Allogeneic Stem Cell Transplant Recipients: A Quality Improvement Project”

  • “Team Science”

  • “Ceramides as Novel Biomarkers of Cardiometabolic Conditions”

  • “Heart Failure Epidemiology and Outcomes Statistics An Updated 2024 Report from the Heart Failure Society of America”

  • “Heart Failure Epidemiology and Outcomes Statistics, A Report of the Heart Failure Society of America”

  • “Implementation Mapping and Concept Mapping to Explore Guideline Implementation in the Heart Failure Clinic”

  • “Coordinating Resources for a Hybrid Effectiveness and Implementation Trial Across an Integrated Digital Network for Heart Failure”

  • “Creating a Standardized Approach to Program Evaluation in a Magnet Recognized Pediatric Hospital System”

 

 

 

Ali Alahmari | Stem Cell Transplantation | Best Researcher Award

Published on by Cell Biologist

Dr. Ali Alahmari | Stem Cell Transplantation | Best Researcher Award

Kfshrc | Saudi Arabia

Dr. Ali Alahmari is a distinguished consultant in Acute Leukemia, Hematology, Hematopoietic Stem Cell Transplantation (HSCT), and Cellular Therapy at King Faisal Specialist Hospital & Research Centre. He earned his MBBS degree from King Saud University and completed his internship at King Khalid University Hospital. He has held a key consultant position, contributing extensively to the advancement of cellular therapy and bone marrow transplantation in Saudi Arabia. Dr. Alahmari has made significant academic contributions to the field, particularly in hemato-hepatology and sickle cell disease. His research has focused on novel transplant approaches, including haploidentical stem cell transplantation after liver transplantation and donor impact in severe aplastic anemia. He has co-authored over 22 scientific documents, with his work accumulating more than 629 citations and earning an h-index of 12, reflecting the depth and influence of his research. His notable publications include titles such as “Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic anemia“ and “Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction.” Dr. Alahmari’s ongoing efforts continue to shape clinical best practices and research frameworks for hematologic disorders and transplantation medicine in the region.

Profile: Scopus

Featured Publications:

  • “Author Correction: Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction: a case series”

  • “Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic anemia: a study of the SAAWP EBMT”

  • “Emerging need for a hepato-hematology program for patients with sickle cell disease in Saudi Arabia”

  • “Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction: a case series”

  • “Hematopoietic Stem Cell Transplantation in Sickle Cell Disease”

  • “Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation”

  • “Outcomes of human leukocyte antigen matched sibling transplant from consanguineous versus non-consanguineous parents, a single center experience”

Sedigheh Gharbi | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Dr. Sedigheh Gharbi | Stem Cell Research | Best Researcher Award

Dr. Sedigheh Gharbi | Shahid Bahonar University of Kerman, Kerman, Iran | Iran

Assistant Prof. Dr. Sedigheh Gharbi is a dedicated Iranian biologist. She is currently an Assistant Professor at Shahid Bahonar University of Kerman, specializing in molecular biology with a strong focus on non-coding RNAs and their roles in cancer and cardiac regeneration. With over a decade of academic and research experience, Dr. Gharbi has contributed extensively to understanding microRNAs and long non-coding RNAs in disease mechanisms. She is recognized for her work on cardiomyocyte regeneration, cancer biology, and novel RNA regulatory networks. Dr. Gharbi has published numerous peer-reviewed articles, demonstrating her commitment to advancing biomedical research. Her research aims to translate molecular findings into potential therapeutic strategies, especially in oncology and regenerative medicine. She is also known for mentoring students and collaborating internationally to foster innovation in life sciences.

Publication Profile: 

Google Scholar

Education:

Dr. Sedigheh Gharbi completed her PhD in Molecular Biology at Tarbiat Modares University, Tehran. Her doctoral thesis focused on the microRNA expression profile alterations in serum and urine of sulfur mustard victims, under the supervision of Prof. Seyyed Javad Mowla. This work laid the foundation for her expertise in microRNAs and their diagnostic potential in toxicology and disease. Before her PhD, she earned a Master of Science degree from the University of Isfahan, where she conducted research on the mutational screening of the PIK3CA gene in breast cancer patients under Prof. Manoochehr Tavassoli. This early work sparked her interest in cancer genetics and molecular markers. Her education combined advanced molecular techniques with applied biomedical research, equipping her with the skills necessary for innovative studies in RNA biology and its implications in human diseases.

Experienc:

Since 2014, Dr. Gharbi has served as an Assistant Professor at Shahid Bahonar University of Kerman, where she lectures and leads research in molecular biology and cancer genetics. Her academic career is marked by active involvement in teaching, supervising graduate students, and securing research projects. She has a proven record in managing interdisciplinary studies focused on cardiomyocyte regeneration and RNA biology. Dr. Gharbi’s research experience spans molecular profiling of cancer biomarkers, non-coding RNA regulatory networks, and nanotechnology applications in drug delivery. She has collaborated with multiple research teams nationally and internationally, contributing to both fundamental science and translational medicine. Her role involves experimental design, bioinformatics analysis, and dissemination of findings through scientific publications and conferences. Dr. Gharbi’s experience in mentoring young scientists and publishing extensively positions her as a leader in her field.

Research Focus:

Dr. Gharbi’s primary research focus lies in the regulatory roles of non-coding RNAs—especially microRNAs (miRNAs) and long non-coding RNAs (lncRNAs)—in disease pathogenesis and therapy. She investigates cardiomyocyte regeneration by exploring how lncRNAs influence cell cycle progression, aiming to improve heart repair after injury. In oncology, her research centers on the regulatory structure of E-cadherin and the involvement of non-coding RNAs in cancer progression and management. Additionally, Dr. Gharbi is dedicated to identifying novel miRNAs and elucidating their functions in cellular processes like apoptosis and proliferation. Her work integrates molecular biology techniques with bioinformatics to uncover RNA-based biomarkers and therapeutic targets. The intersection of nanotechnology and RNA therapeutics is another emerging area in her studies, aiming to optimize cancer treatment delivery systems. Overall, her research contributes to understanding complex gene regulation mechanisms and developing RNA-based precision medicine strategies.

Publications Top Notes: 

  1. Mir-542 As A Potential and Promising Therapeutic Target For HPV-Positive Cervical Cancers

  2. CircPAN3/miR-221/PTEN Axis and Apoptosis in Myocardial Infarction: Quercetin’s Regulatory Effects

  3. Controlled cytotoxicity of Ag-GO nanocomposite biosynthesized using black peel pomegranate extract against MCF-7 cell line

  4. Characterization of the first microRNA in human CDH1 that affects cell cycle and apoptosis and indicates breast cancers progression

  5. Curcumin loaded on graphene nanosheets induced cell death in mammospheres from MCF-7 and primary breast tumor cells

  6. Bioinformatics Prediction of microRNAs Regulating Epithelial-to-Mesenchymal Transition in Cancer Cells

  7. Secondary toxic effect of graphene oxide and graphene quantum dots alters the expression of miR-21 and miR-29a in human cell lines

  8. Statins: Complex outcomes but increasingly helpful treatment options for patients

  9. Synthesis and characterization of d10 transition metal complexes in bulk and nano scales: DNA binding, molecular docking and anticancer activity against MCF-7 cell line

  10.  Quantification of circulating miR-517c-3p and miR-210-3p levels in preeclampsia

Conclusion:

In conclusion, Assistant Prof. Dr. Sedigheh Gharbi is highly suitable for the Best Researcher Award based on her consistent track record of innovative, impactful research and academic contributions. Her focus on molecular biology, especially the regulatory roles of non-coding RNAs in cancer and cardiac regeneration, addresses some of the most challenging issues in contemporary biomedical science. Her extensive publication record in reputable journals reflects the quality and significance of her work. While there are opportunities for further enhancing her international collaborations, funding portfolio, and translational efforts, her current achievements already mark her as a leading researcher with great potential for continued contributions. Awarding her the Best Researcher Award would recognize her scientific excellence and encourage further advancements in her promising research career.

 

Zhaowei Feng | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Dr. Zhaowei Feng | Stem Cell Research | Best Researcher Award

Dr. Zhaowei Feng, The Second Affiliated Hospital of Xuzhou Medical University, China

Zhaowei Feng is a dedicated biomedical researcher specializing in neurobiology and pharmacology, currently serving as an Assistant Researcher at The Second Affiliated Hospital of Xuzhou Medical University. With a solid academic foundation and a passion for neuroscience, Feng has made significant contributions to understanding mechanisms of neuroprotection and demyelination. His research spans neurodegenerative disease models such as multiple sclerosis and neonatal hypoxia-ischemia, utilizing molecular and cellular biology tools. Known for his collaborative nature and scientific rigor, Feng has co-authored multiple peer-reviewed articles in prestigious journals and has played pivotal roles in various national and municipal-level research projects. He is particularly recognized for co-first authorship in several studies, reflecting leadership in experimental design and data analysis. His growing influence in the field is further supported by ongoing funded projects and a research trajectory aimed at translational outcomes. Feng is committed to continuing impactful research that bridges bench science with clinical applications.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Strong Research Focus in Neurobiology 🧠
    Zhaowei Feng has a consistent and impactful research portfolio in neurobiology, particularly in myelination, ischemia-reperfusion injury, and glutamate signaling. His work is highly relevant in addressing diseases like multiple sclerosis and neonatal hypoxia-ischemia encephalopathy.

  2. Publications in High-Impact Journals 📚
    He has co-authored several peer-reviewed journal articles in reputable journals such as Phytomedicine, Pharmacology, Oncology Reports, and Frontiers. His contributions as co-first author in multiple papers reflect significant involvement in study design and experimentation.

  3. Independent Researcher Role 🧪
    He currently serves as a Principal Investigator for a municipal-level research project funded by the Xuzhou Health Commission, demonstrating trust in his leadership and research direction.

  4. Multidisciplinary Expertise 🔬
    His research integrates pharmacology, molecular biology, and neuroscience, covering diverse mechanisms like PPARγ signaling, SUMOylation, and ferroptosis, which enhances translational potential.

  5. Rapid Academic Growth 🚀
    Transitioning quickly from a Master’s student (2019–2022) to Assistant Researcher and PI (since 2022) shows a fast-tracked academic trajectory.

⚠️ Areas for Improvement:

  1. Need for More First-Author and Corresponding-Author Papers ✍️
    While co-first authorship is commendable, a stronger emphasis on sole first or corresponding authorship in future publications would establish more scientific independence.

  2. Limited Recognition at National Level 🏅
    Most current funding and achievements are at the municipal level. Applying for national or international grants (e.g., NSFC, NIH) would elevate his research profile.

  3. Postdoctoral Training or Collaboration Abroad 🌍
    Gaining international experience or collaborating with global research centers could broaden perspectives and techniques, increasing citation impact and networking.

  4. More Diversified Research Outputs 📊
    Exploring patents, clinical trials, or translational research outcomes could further demonstrate innovation and application potential.

🎓 Education:

Zhaowei Feng began his academic journey in the biological sciences at Xuzhou Medical University, where he earned his Bachelor’s degree between 2014 and 2018. He further pursued a Master’s degree in Neurobiology at the same institution from September 2019 to July 2022. His graduate studies were marked by an intensive focus on neurodegenerative mechanisms, including demyelination and neuroinflammation, with particular attention to cuprizone-induced and ischemia-reperfusion mouse models. His research also explored glutamate transport regulation, the PPARγ pathway, and oligodendrocyte differentiation. His educational foundation not only provided him with technical proficiency in experimental neuroscience but also cultivated a strong understanding of translational biomedical research. Through rigorous coursework, laboratory experience, and thesis writing, Feng developed a robust academic profile that seamlessly transitioned into his research career. His educational journey reflects consistent dedication and a clear trajectory towards clinical and experimental neurobiology.

🧪 Experience:

Since September 2022, Zhaowei Feng has been working as an Assistant Researcher at The Second Affiliated Hospital of Xuzhou Medical University. His role involves leading preclinical studies, managing collaborative projects, and mentoring junior researchers. Feng has also served as Principal Investigator on a municipal-level research grant focusing on blood-brain barrier damage post-transplantation. He actively participates in multiple interdisciplinary studies involving neurodevelopment, myelination, and pharmacological interventions. Prior to his current role, his Master’s research provided hands-on experience with animal models, molecular techniques, and data analysis in neurobiology. Feng has authored or co-authored numerous research papers, some as co-first author, contributing significantly to study design and execution. He is also involved in translational research projects that aim to bridge laboratory findings with clinical therapies. His work ethic, attention to detail, and innovative approach make him a valuable contributor to the field of neurobiological research.

🏅 Awards and Honors:

Zhaowei Feng has been recognized for his scientific contributions through both academic and research-oriented accolades. Notably, he is the recipient of a research grant from the Xuzhou Municipal Health Commission (Project No. XWKYHT20230029), focusing on cerebral ischemia-reperfusion and blood-brain barrier injury. Though early in his professional career, his selection as Principal Investigator on this project signifies trust in his leadership and expertise. Several of his publications in high-impact journals list him as co-first author—an honor that highlights his equal contribution in rigorous experimental work. While he has yet to receive national awards such as from the Natural Science Foundation, his steady academic output and funded research projects mark a strong trajectory. His growing publication record and role in significant studies position him as a rising talent in the biomedical field. Future honors are likely as his research continues to address key questions in neuroscience and pharmacology.

🔬 Research Focus:

Zhaowei Feng’s research centers on neuroprotection, demyelination, and neuroinflammation, with a particular focus on the mechanisms underlying multiple sclerosis, ischemic brain injury, and neonatal encephalopathy. His studies often employ animal models such as cuprizone-induced demyelination and hypoxia-ischemia to explore therapeutic targets. Feng is particularly interested in the regulation of oligodendrocyte differentiation and the role of glutamate transporters, signaling molecules like PPARγ, and pathways involving Wnt/β-catenin and SUMOylation. Additionally, he has investigated compounds such as diosgenin and alpha-asaronol for their neuroprotective and remyelination-promoting effects. His work also extends into cancer biology, with studies on ferroptosis and protein regulation in squamous cell carcinoma. By integrating molecular biology, pharmacology, and neurodevelopmental research, Feng aims to contribute to the discovery of new treatments for central nervous system disorders. His current and future research is geared toward translational medicine that bridges laboratory science with clinical applications.

📚 Publication Top Notes:

  1. 🧠 Alpha-Asaronol Alleviates Dysmyelination by Enhancing Glutamate Transport via PPARγ-GLT-1 Signaling in Neonatal Hypoxia-Ischemia (Pharmacology, 2022)

  2. 🧬 C1q Inhibits Differentiation of Oligodendrocyte Progenitor Cells via Wnt/β-Catenin Signaling (Biomedicine & Pharmacotherapy, 2023)

  3. 🧪 Alpha-Asaronol Promoted OPC Differentiation and Improved Myelination as a PPARγ Activator (Frontiers, 2023)

  4. 🧫 Diosgenin Promoted OPC Differentiation by Blocking GLUR2/GAPDH Interaction in Pilocarpine-Induced Epilepsy Rats (Phytomedicine, 2025)

  5. 🧬 Netrin-4 Mediates Piezo1 Inactivation and YAP Signaling Alleviation in Cerebral Ischemia-Reperfusion (Oncology Reports)

  6. 🔬 SENP1 Inhibits Ferroptosis and Promotes Head and Neck Squamous Cell Carcinoma by Regulating ACSL4 Protein (Molecular Oncology, 2023)

  7. 🧪 SUMO1-Mediated Stabilization Enhances Protein Function in Neuroinflammatory Models (Unspecified Journal)

  8. 🧠 Signaling Activation in a Cuprizone-Induced Mouse Model of Multiple Sclerosis (Unspecified Journal)

📌 Conclusion:

Zhaowei Feng is a highly promising early-career researcher with a clear scientific focus, a growing publication record, and demonstrated ability to lead independent research. His work addresses critical challenges in neurobiology and pharmacology, making a tangible impact in both experimental and translational medicine. With continued progression—especially toward national-level recognition and senior authorship—he has the potential to become a leader in his field.

Zhi Guo | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Prof. Dr Zhi Guo | Stem Cell Research | Best Researcher Award

Prof. Dr Zhi Guo | Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital | China

Dr. Zhi Guo is a distinguished expert in hematology with over 25 years of clinical and academic experience. Currently serving as Director, Academic Leader, Chief Physician, and Professor at the Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, he has been instrumental in advancing hematologic malignancy treatments in China. With extensive expertise in hematopoietic stem cell transplantation, Dr. Guo has successfully performed more than 1,300 transplant cases. He began his career at the PLA Army General Hospital, serving there for nearly two decades before transitioning to his current role. A prolific researcher, he has authored over 10 peer-reviewed publications and five books, contributing substantially to the understanding of CAR-T therapy, gut microbiota, and transplantation immunology. He is an active member of major national and international hematology associations and plays a vital role in formulating clinical consensus and guidelines in China.

publication profile:

Scopus

Strengths for the Award:

Dr. Zhi Guo exemplifies the qualities of an outstanding medical researcher and clinician. With nearly 25 years of clinical experience in hematology and over 20 years in hematopoietic stem cell transplantation, he stands out as a national leader in this field. His performance of more than 1,300 transplants, along with a strong academic footprint, including 10 SCI-indexed publications in 2024–2025, demonstrates both depth and innovation in his research. He has also contributed to national expert consensus and clinical guidelines, particularly in CAR-T therapy and intestinal microecology. Dr. Guo’s leadership roles across national academic committees and his active membership in the American Society of Hematology further highlight his international impact and collaborative influence.

Areas for Improvement:

While Dr. Guo’s achievements in clinical practice and research are significant, opportunities exist to increase global visibility by expanding his research collaborations internationally and publishing in higher-impact journals beyond regional scopes. Additionally, while five books have been authored, the addition of patents or translational innovations could enhance his profile in the realm of research commercialization and practical medical technologies.

Education :

Dr. Zhi Guo holds a strong academic background in clinical medicine and medical research. He earned his Bachelor’s degree in Medicine from Tongji Medical College in 2000. Subsequently, he pursued his postgraduate medical studies at the Third Military Medical University, completing it in 2007. His academic journey culminated with the attainment of a Doctor of Medicine (MD) degree from Wuhan University of Science and Technology. His education laid a strong foundation in hematology and clinical research methodologies. Each step in his educational path was marked by an emphasis on academic rigor and clinical competence, preparing him for a leadership role in medical science and hematologic research. His multidisciplinary background has enabled him to integrate clinical insights with advanced laboratory-based innovations, contributing to national-level guidelines and the development of cutting-edge CAR-T cell therapies and transplantation techniques.

Experience :

Dr. Zhi Guo brings nearly 25 years of clinical, academic, and leadership experience in the field of hematology. He began his professional journey at the PLA Army General Hospital, where he served from 2000 to 2018. During this period, he honed his clinical and procedural expertise in managing complex hematologic disorders. Since 2018, he has been leading the Department of Hematology at Huazhong University of Science and Technology Union Shenzhen Hospital as Director, Academic Leader, and Chief Physician. His rich experience includes more than 1,300 hematopoietic stem cell transplantations, encompassing autologous, allogeneic, and CAR-T integrated therapies. His leadership extends beyond clinical care, as he also mentors postgraduate medical students and leads multiple national and institutional research projects. Dr. Guo’s practical experience is balanced with his strategic contributions to medical consensus formulation and research-driven policy initiatives in cancer and immune-hematological disorders.

Research Focus :

Dr. Zhi Guo’s research centers on hematologic malignancies and hematopoietic stem cell transplantation, particularly the integration of cellular immunotherapy such as CAR-T cell treatments. His recent work includes pioneering anti-CD19, anti-CD7, and anti-BCMA CAR-T therapies for lymphomas and leukemias. Additionally, he has investigated the interplay between microbiota and immune modulation in transplantation, highlighting the role of gut and oral microbiomes in patient outcomes. His contributions have influenced the development of clinical guidelines for microbiota-related diagnostics and treatments in oncology. With more than 10 high-impact journal publications and ongoing projects in translational medicine, Dr. Guo’s work combines laboratory innovation with patient-centered applications. He has also authored expert consensus documents and national guidelines, helping shape China’s hematology and transplantation protocols. His commitment to interdisciplinary collaboration, clinical innovation, and translational research underscores his leading role in advancing modern hematology.

Publications Top Notes:

  1. 🧬 In vitro validation of anti-CD19 CAR-T cells with LSD1 shRNA for DLBCL – Front Immunol, 2025

  2. 🩸 Case of T-ALL treated with chemo + anti-CD7 CAR-T (retroviral vector) – Front Immunol, 2025

  3. 👶 Shaping oral/intestinal microbiota & immunity in first 1,000 days of life – Front Pediatr, 2025

  4. 💩 Fecal microbiota transplantation in acute GVHD treatment – J Cancer Res Ther, 2024

  5. 🔬 Chinese consensus on gut microecology lab standards – Exp Ther Med, 2024

  6. 🧪 2024 Chinese guidelines for intestinal microecology in cancer – J Cancer Res Ther, 2024

  7. 🧫 First MM case treated with ASCT + anti-BCMA CAR-T (retrovirus) – Heliyon, 2024

  8. 🧾 Rapid response in relapsed FL to anti-CD19 CAR-T with CMV – Int Immunopharmacol, 2024

  9. 🦷 Prognostic impact of oral microbiome in cancer survival – meta-analysis – Syst Rev, 2024

  10. 🧍‍⚕️ Expert consensus on gut microbiome & hematopoietic stem cell transplantation – Clin Transplant, 2024

Conclusion:

In conclusion, Dr. Zhi Guo is highly suitable for the Best Researcher Award. His combination of clinical excellence, academic leadership, and impactful research in hematology and stem cell transplantation positions him among the top contributors in this specialized field. With ongoing research in CAR-T cell therapies, microbiota influence on transplantation, and immuno-oncology, Dr. Guo continues to shape the future of hematologic cancer care. Recognizing his contributions with this award would be both fitting and encouraging for continued innovation in this vital area of medicine.